Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy
- 31 May 2004
- journal article
- clinical trial
- Published by Elsevier BV in Brain, Behavior, and Immunity
- Vol. 18 (3), 205-213
- https://doi.org/10.1016/j.bbi.2003.11.004
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Neuropsychological Performance and Mood States following Acute Interferon-β-1b Administration in Healthy MalesNeuropsychobiology, 2002
- Neurobehavioral Effects of Interferon-α in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom DimensionsNeuropsychopharmacology, 2002
- Sleep disturbances and mood disorders: An epidemiologic perspectiveDepression and Anxiety, 2001
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Neuropsychiatric symptoms during treatment with interleukin-2The Lancet, 1993
- Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?Published by American Medical Association (AMA) ,1989
- Grade Scores of the Montgomery—Åsberg Depression and the Clinical Anxiety ScalesThe British Journal of Psychiatry, 1986
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Assessing social support: The Social Support Questionnaire.Journal of Personality and Social Psychology, 1983
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979